
No direct correlation between cardiovascular events and COVID-19 exposure and vaccination: Study
Amid mounting public anxiety over the rising trend of sudden cardiovascular events (heart attack, sudden cardiac death) post-COVID-19 pandemic, the Karnataka government had in February this year set up an expert committee headed by Jayadeva Director K. S. Ravindranath to evaluate the temporal and potential causal links with prior SARS-CoV-2 infection and/or COVID-19 vaccination.
The cross-sectional study involving 251 patients, including 32 females, aged below 45 years, was aimed at presenting evidence-based insights, identifying risk factors, and proposing recommendations for surveillance and prevention. The committee submitted its report to Harsh Gupta, Principal Secretary, Health and Family Welfare on July 4.
Under-recognised mechanisms
'Although conventional risk factors, such as hypertension, diabetes, dyslipidemia, and smoking, remain prevalent in a majority of the 251 patients, a significant minority of patients presented with none of these, suggesting the possible involvement of novel or under-recognized mechanisms,' Dr Ravindranath told The Hindu.
According to the report, while 87 of the patients were diabetic, 102 were hypertensive, 35 were having cholesterol disorder, 40 had family history of heart diseases, 111 were smokers, and 77 patients did not have any of the conventional risk factors. As many as 19 out of 251 patients had a history of previous COVID-19 infection. Of the 19, seven each had diabetes and hypertension, two had a family history, eight had no risk factors.
Almost all (249) of the 251 patients had been vaccinated against COVID. While 53 received only one dose, 180 received two doses, and 17 received all three doses of a vaccine. As many as 144 had been vaccinated with Covishield, 64 with Covaxin, and 52 were unaware of which vaccine they had received.
Comparative data
To compare the risk factor profile of similar premature coronary artery disease patients prior to the pandemic, the team used data from the institute's Premature Coronary Artery Disease (PCAD) among the young registry maintained at the institute between April 1, 2019 and May 31, 2019. As the PCAD registry was maintained for patients aged under 40 years, a subset of patients from the present study aged below 40 years were grouped and compared with the 2019 age and sex-matched population.
Analysing all national and international peer reviewed scientific literature, journal articles, clinical studies and clinical registries to study the possible association of sudden cardiovascular events with past history of COVID-19 infection and vaccination, the Jayadeva committee noted that most studies and reports published globally have also not found any causal association between COVID vaccination and sudden cardiovascular events. 'On the contrary, COVID vaccination has been shown to be protective against cardiac events in the long term,' the report stated.
No single cause
'Our study has not found any single cause behind the observed rise in sudden cardiac deaths. Rather, it appears to be a multi-factorial issue, with behavioural, genetic, and environmental risks. While in the immediate post-COVID phase, there is an increase in the incidence of sudden cardiovascular events due to a pro-inflammatory state, the same cannot be held to be true in the long term (>1 year). It has been three years since the end of the pandemic,' Dr Ravindranath said.
He said current data does not support the belief that 'long COVID' is responsible for the rise in sudden cardiovascular events among the young. 'Rather, a rise in the prevalence of the common risk factors that lead to cardiovascular disease (hypertension, diabetes, smoking , dyslipidemia) is the best explanation for the rise in sudden cardiovascular events. In light of these findings, a multi-faceted public health strategy is essential,' he asserted.
Recommendations
Pointing out that the strategy should include establishing a robust surveillance system for sudden cardiac deaths, particularly among young adults, the Jayadeva director said implementing autopsy-based registries and integrating early cardiovascular screening at the school level is vital.
'Importantly, large-scale, prospective, multicentric studies are needed to better delineate the long-term cardiovascular effects of both COVID-19 infection and vaccination,' he explained.
Recommendations
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hans India
an hour ago
- Hans India
Piyush Goyal slams CM for insulting Indian scientists, drugmakers
Bengaluru: Union Commerce and Industry Minister Piyush Goyal on Saturday criticised Karnataka Chief Minister Siddaramaiah for suggesting a link between Covid-19 vaccines developed in India and the sudden deaths. Speaking to the media, on the sidelines of IIT Madras Alumni Association's Sangam 2025 event in Bengaluru, Piyush Goyal praised the Indian scientists for developing Covid vaccine in record time and the pharmaceutical sector for making it cost-effective. 'Fake narratives can't dilute the extraordinary work done by our scientists and the pharma industry in our fight against Covid,' said Goyal. 'Such a big country like India was able to provide 250 crore vaccines for free, because the companies of our country had the strength to make the vaccine at a much lower cost,' he added. His comments come in the wake of Siddaramaiah's recent post on social media platform X on 'the hasty approval and distribution of the Covid vaccine to the public'. The CM linked it to the more than 20 heart attack-related deaths seen in Karnataka's Hassan district in just 40 days. The Union Health Ministry, along with several scientists as well as pharma associations, has denied any link between Covid vaccines and the reported sudden deaths. A joint clarification from the Indian Council of Medical Research (ICMR), All India Institute of Medical Sciences (AIIMS), and the National Centre for Disease Control (NCDC) stated that ongoing surveillance and analyses have not revealed any significant deviation in patterns of cardiac-related deaths since before the pandemic. 'I feel that the Chief Minister here does not disrespect, he insults, and when he insults our scientists, our pharmacy, then I do not know what is the motive behind it?' Goyal said. 'Apologise to the Indian scientists and the pharmaceutical sector,' he added. He also asked whether the CM and the Congress are working at the behest of foreign powers. Are these the foreign powers whose agenda they are running here, are the foreign powers who want to lure India's pharmacy, are they troubled by India's economic progress and development,' Goyal said.


Hans India
an hour ago
- Hans India
CM ran to Centre for Covid jab but now questions vaccine
Bengaluru: Rejecting Chief Minister Siddaramaiah's claim linking the rapid rollout of Covid vaccinations to heart attack cases, BJP leader D. V. Sadananda Gowda on Saturday said that the Congress leader was among the first to get vaccinated and is perfectly healthy. Former Chief Minister Gowda taunted Siddaramaiah, saying, 'It is because of the good health he gained from the Covid vaccine that Siddaramaiah is now claiming he will complete the full five-year term as Chief Minister and even lead the Congress to victory in the next election.' 'As soon as the vaccination drive began, Siddaramaiah ran to the Centre and got himself vaccinated. Nothing has happened to his body. We sincerely wish that nothing ever does,' Gowda stated. However, CM Siddaramaiah must exercise restraint, Gowda said. Responding to this, Kiran Majumdar Shaw stated that, 'COVID-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation.' On Shaw's assertion, Chief Minister Siddaramaiah remarked that seeking clarity does not amount to spreading misinformation.


Economic Times
2 hours ago
- Economic Times
Biotech boom: More Indian students head abroad for biotechnology degrees
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Specialisations in Demand Popular in NRI New Delhi: The number of Indian students applying for biotechnology studies abroad is growing. They're drawn by the opportunities the subject offers as large corporations and governments pour more funds into research for gene therapies , vaccines and weight-loss drugs, according to experts."There is a growing interest among Indian students looking to pursue biotechnology programmes in the UK, the US, Canada and Australia," said Piyush Kumar, regional director for South Asia at IDP Education. "Notably, biotech and life sciences applicants have made up about 40% of the total STEM (science, technology, engineering and mathematics) cohort from India to the UK in the past one-two years-a significant and telling trend."The Covid-19 pandemic is seen as a turning point. "The tangible success of mRNA vaccines, rapid diagnostics and gene therapies turned biotech into a symbol of real-world impact," said Rahul Subramaniam, co-founder of Athena Education. "Students started seeing scientists like Katalin Kariko and Drew Weissman as modern heroes." Gene editing, synthetic biology and computational biology have emerged as the top draws, said Akshay Chaturvedi, founder of LeverageEdu."These are seeing nearly 1.5x to 2x more student interest than they did a few years ago," said Chaturvedi. "Agricultural biotech and pharma R&D are also seeing increased traction, particularly among students from tier-2 cities with roots in agriculture or pharmacy backgrounds."Notable is the shift in student profiles. Many are now coming from interdisciplinary backgrounds—engineering, computer science and pure sciences—often with research internships or Olympiad projects under their belt.'Our biotech aspirants, over the last two years, have often hailed from engineering or computer science backgrounds, particularly those interested in bioinformatics, computational biology and systems biology,' said Subramaniam of Athena said students are choosing destinations not just for the brand name, but for access to research grants, lab rotations, incubator support and real pathways into the bioeconomy workforce. High on students' lists are universities in the US, UK, Germany, Canada, Australia and even Singapore, with post-study work rights, research assistantships and startup incubation support influencing decisions. 'It's a very pragmatic generation,' he to Sanjog Anand, cofounder of Rostrum Education, demand is highest for specialisations such as medical biotechnology, bioinformatics, synthetic biology, gene editing and pharma research and development.